S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Oxygen Biotherapeutics Enters License and Supply Agreement for Dermacyte® Products with the Cosmetics Division of Valor SA (2013/2/11)|
|Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013 (2013/3/18)|
|Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO & Investor Conference on February 11 (2013/1/30)|
|Oxygen Biotherapeutics Announces Tentative Settlement of Litigation (2013/2/20)|
|Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast (2013/3/13)|
|Oxygen Biotherapeutics and the U.S. Army Institute of Surgical Research Sign a Cooperative Research and Development Agreement to Study the Effects of Oxycyte® on Ex Vivo Platelet Function (2013/2/6)|
|Oxygen Biotherapeutics Announces It is Set to Begin Enrolling Patients in the Second Cohort of Its STOP-TBI Clinical Trial in Israel (2013/4/30)|
|Oxygen Biotherapeutics Announces 20:1 Reverse Stock Split Effective After Market Close on May 10th (2013/5/10)|
|Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer (2013/5/21)|
|Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision (2013/5/16)|
Click above to view more mutual fund data and stats for oxbt - Oxygen Biotherapeutics, Inc..